| Drug Type Small molecule drug | 
| Synonyms- | 
| Target | 
| Action agonists, antagonists | 
| Mechanism CGAS agonists(cyclic GMP-AMP synthase agonists), STING agonists(Stimulator of interferon genes agonists), TRPV3 antagonists(Transient receptor potential cation channel subfamily V member 3 antagonists) | 
| Therapeutic Areas | 
| Active Indication | 
| Inactive Indication- | 
| Originator Organization | 
| Active Organization | 
| Inactive Organization- | 
| License Organization- | 
| Drug Highest PhasePreclinical | 
| First Approval Date- | 
| Regulation- | 
| Molecular FormulaC18H16O8 | 
| InChIKeyDOUMFZQKYFQNTF-WUTVXBCWSA-N | 
| CAS Registry20283-92-5 | 
| Indication | Highest Phase | Country/Location | Organization | Date | 
|---|---|---|---|---|
| Osteoporosis | Preclinical | China  | 24 Jun 2025 | |
| Squamous cell carcinoma of the oral cavity | Preclinical | Portugal  | 01 Jun 2025 | |
| Colorectal Cancer | Preclinical | China  | 24 May 2025 | |
| Dermatitis | Preclinical | China  | 21 May 2025 | |
| Pseudorabies | Preclinical | China  | 17 Mar 2025 | |
| Triple Negative Breast Cancer | Preclinical | China  | 25 Feb 2025 | |
| Triple Negative Breast Cancer | Preclinical | China  | 25 Feb 2025 | 





